Balaji Amines Limited announced its financial results for the third quarter and nine months ended December 31, 2025 (Q3FY26). For Q3FY26, the consolidated revenue from operations stood at ₹331.30 crore, a slight decrease from ₹340.55 crore in Q2FY26. Total volumes were maintained at 25,894 MT, similar to Q3FY25. Amines volumes were 6,993 MT, Amines Derivatives volumes were 9,223 MT, and Specialty Chemicals volumes were 9,678 MT. Consolidated EBITDA for Q3FY26 was ₹61.67 crore, with an EBITDA margin of 18.34%. Profit After Tax (PAT) was ₹30.76 crore, and diluted Earnings Per Share (EPS) was ₹9.49. On a standalone basis, the company reported zero debt. Standalone revenue was ₹306.57 crore, with EBITDA at ₹60.08 crore and PAT at ₹32.41 crore. Several new projects are under execution and expected to be commissioned during FY 2026-27, including a Di Methyl Ether (DME) Plant, an N-Methyl Morpholine (NMM) plant with a capacity of 5000 TPA, and an improved process-based Acetonitrile (ACN) plant. These projects will be funded through internal accruals. A significant expansion of ₹750 crore is underway at its subsidiary, Balaji Speciality Chemicals Limited. This expansion includes various value-added products like Hydrogen Cyanide (HCN), Sodium Cyanide (NaCN), and Ethylene Diamine Tetra Acetic Acid (EDTA). The Maharashtra government has granted Mega Project status to this expansion. Specifically, a brownfield project for EDA-based products at Unit-I is expected to be commissioned by September 2026. A greenfield project at Unit-II for HCN, NaCN, and EDTA is expected to be commissioned before December 2026. The company also highlighted its market leadership in Methylamines production, with installed capacity increasing to 88,000 TPA from 48,000 TPA. The Methyl Amines plant at Unit IV was commissioned on November 10, 2024. The Dimethyl Ether (DME) plant with a capacity of 100,000 TPA is under erection and scheduled for commissioning in FY 2025-26. For 9MFY26, consolidated revenue was ₹1051.26 crore, and PAT was ₹104.39 crore. Standalone revenue for 9MFY26 was ₹949.39 crore, with PAT at ₹103.66 crore. Balaji Amines Limited also presented its financial performance, historical data, product portfolio, manufacturing capacities, and strategic focus on value-added products and R&D. The company emphasized its zero-debt status on a standalone basis and its strong financial discipline.
